Document Detail


Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.
MedLine Citation:
PMID:  7986198     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Two human colon carcinoma drug resistant clones (LoVo-IDA-1 and LoVo-IDA-2) were selected by continuous pressure of LoVo parent cell lines to idarubicin (IDA). Both cell sublines exhibited a typical multidrug resistance (MDR) phenotype but, despite IDA selection, the resistance index (RIext) was higher for daunorubicin (DAU) (RIext = 101-112) than for IDA (RIext = 20-23). A similar pattern of cross-resistance was also observed in two (DOX) doxorubicin-selected LoVo cell lines (LoVo-DOX-1 and LoVo-DOX-2). All the MDR cell lines exhibited decreased drug accumulation and increased intracellular drug tolerance as evidenced by the greater intracellular amount of drug required to cause a 50% growth inhibition (IC50int) compared to their parent cell line. The differences between DAU and IDA RIext exhibited by MDR cells were a function of intracellular resistance. DAU IC50int was 13.9 and 14.9 times higher in LoVo-IDA-1,2 and 6.4 and 6.2 in LoVo-DOX-1,2 cell lines, respectively, than in LoVo-sensitive cells, whereas IDA IC50int was only 3.6 and 3.2 times higher in LoVo-IDA-1,2 and 2.2 and 2.3 in LoVo-DOX-1,2 cell lines, respectively. Conversely, variations in IDA accumulation between resistant and sensitive cells were similar to those observed for DAU [the ratios between DAU uptake in sensitive and resistant cells were almost identical (P = NS) to those observed for IDA]. Differences between IDA and DAU intracellular distribution accounted for the relatively higher DAU intracellular resistance. In fact nuclear/cytoplasmic (N/C) DAU fluorescence ratio was higher (P < 0.01) in sensitive (N/C = 3.4 +/- 2.7) than in MDR cells (N/C ranging from 0.31 +/- 0.2 to 0.41 +/- 0.1). In contrast, no significant (P = NS) differences were observed in IDA N/C ratios between sensitive and MDR cells (N/C ranging from 0.16 +/- 0.1 to 0.20 +/- 0.1). In MDR cells, 1-hr VER (10 microM) treatment partially reverted both DAU N/C ratios and intracellular DAU resistance but neither changes in IDA N/C ratios nor variation in intracellular IDA resistance were observed following VER exposure. In conclusion, the greater intracellular drug tolerance that MDR cells show for DAU compared to IDA makes IDA more effective than DAU in MDR cells overexpressing P-glycoprotein (P-gp).
Authors:
G Toffoli; F Simone; M Gigante; M Boiocchi
Related Documents :
19379318 - Dexamethasone treatment of a canine, but not human, tumour cell line increases chemores...
20411408 - Novel mixed polymeric micelles for enhancing delivery of anticancer drug and overcoming...
19725928 - Involvement of abc transporters in melanogenesis and the development of multidrug resis...
1517798 - Fluorescent dye rhodamine 6g as a molecular probe to study drug resistance of c6 rat gl...
20878478 - Ppgalnact2 participating in vanadium-induced hl-60 cell differentiation.
22266308 - Recombinant fusion protein of albumin-retinol binding protein inactivates stellate cells.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Biochemical pharmacology     Volume:  48     ISSN:  0006-2952     ISO Abbreviation:  Biochem. Pharmacol.     Publication Date:  1994 Nov 
Date Detail:
Created Date:  1994-12-30     Completed Date:  1994-12-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0101032     Medline TA:  Biochem Pharmacol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1871-81     Citation Subset:  IM    
Affiliation:
Division of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano (PN), Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Affinity Labels
Azides
Biological Transport
Cell Membrane / metabolism
Cell Nucleus / enzymology
Clone Cells
Colonic Neoplasms / drug therapy,  metabolism,  pathology*
DNA Topoisomerases, Type II / metabolism
Daunorubicin / metabolism,  pharmacology*
Dihydropyridines
Drug Resistance, Multiple* / genetics
Fluorescence
Humans
Idarubicin / metabolism,  pharmacology*
P-Glycoprotein / metabolism
Tumor Cells, Cultured
Chemical
Reg. No./Substance:
0/Affinity Labels; 0/Azides; 0/Dihydropyridines; 0/P-Glycoprotein; 20830-81-3/Daunorubicin; 58957-92-9/Idarubicin; 90523-31-2/azidopine; EC 5.99.1.3/DNA Topoisomerases, Type II

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of m...
Next Document:  Pyrrolidine dithiocarbamate, a potent inhibitor of nuclear factor kappa B (NF-kappa B) activation, p...